Existing drugs can sometimes be repurposed to treat rare diseases. But making that match can be hard — and the financial incentives are weak. Guest host Steve Levitt tries to solve the puzzle. He speaks with our own Professor Chris Snyder about his work as one of the directors of the University of Chicago Market Shaping Accelerator, or M.S.A.